Veracyte, Inc. (VCYT)
- Previous Close
28.49 - Open
28.54 - Bid 20.31 x 200
- Ask 35.57 x 200
- Day's Range
27.61 - 28.80 - 52 Week Range
19.73 - 47.32 - Volume
1,059,025 - Avg. Volume
1,085,732 - Market Cap (intraday)
2.231B - Beta (5Y Monthly) 2.15
- PE Ratio (TTM)
67.83 - EPS (TTM)
0.42 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
40.50
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
www.veracyte.com824
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: VCYT
View MorePerformance Overview: VCYT
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VCYT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VCYT
View MoreValuation Measures
Market Cap
2.23B
Enterprise Value
1.99B
Trailing P/E
67.83
Forward P/E
21.37
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.89
Price/Book (mrq)
1.87
Enterprise Value/Revenue
4.30
Enterprise Value/EBITDA
37.07
Financial Highlights
Profitability and Income Statement
Profit Margin
7.13%
Return on Assets (ttm)
1.94%
Return on Equity (ttm)
2.86%
Revenue (ttm)
463.39M
Net Income Avi to Common (ttm)
33.05M
Diluted EPS (ttm)
0.42
Balance Sheet and Cash Flow
Total Cash (mrq)
287.36M
Total Debt/Equity (mrq)
4.23%
Levered Free Cash Flow (ttm)
76.93M